Headlines about Compugen (NASDAQ:CGEN) have been trending positive on Friday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Compugen earned a coverage optimism score of 0.33 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.7874466646737 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news articles that may have impacted Accern’s rankings:

Separately, Zacks Investment Research cut Compugen from a “hold” rating to a “sell” rating in a research report on Friday, August 4th.

Compugen (CGEN) traded up 1.91% during trading on Friday, reaching $4.00. The company’s stock had a trading volume of 12,246 shares. The firm has a 50 day moving average of $3.45 and a 200 day moving average of $3.83. The stock’s market capitalization is $204.52 million. Compugen has a 52 week low of $2.60 and a 52 week high of $6.80.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Analysts expect that Compugen will post ($0.73) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/13/compugen-cgen-earns-daily-news-impact-rating-of-0-33.html.

Compugen Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.

Insider Buying and Selling by Quarter for Compugen (NASDAQ:CGEN)

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.